Find out how our hereditary cancer panels use next-generation sequencing to evaluate dozens of genes associated with cancer risk.
Hereditary Colon Cancer Testing - Mayo Clinic Laboratories
Our algorithmic approach aids with the ordering process and guides physicians to ensure the right tests are being ordered at the right time for patients.
Learn more about how Mayo Clinic Laboratories’ genetic testing for pancreatic disease can provide a clearer understanding of a patient’s condition.
Learn about our hereditary cancer test offerings, including single-gene assays that evaluate specific genes already identified in a parent.
December 2022 - Renal - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Renal Pathology.
Yuma Regional Medical Center: Changing perceptions and powering growth - Insights
Looking to elevate laboratory operations, Yuma Regional’s hospital directors established a leadership model that pairs medical and administrative leaders, resulting in a changed perception of the laboratory’s ability to drive profitability...
Therapeutics events - Insights
TherapeuticS Creating the new standard of therapeutic management, together Mayo Clinic Laboratories’ evidence-based toxicology and pharmacogenomic testing
FDA Regulation of Laboratory Developed Tests - Insights
PACE/FL - This webinar will provide a brief history of the FDA’s interest in LDTs and review the new requirements in detail, serving as an introduction to medical device regulations in the context of a clinical laboratory.
Mayo Clinic Laboratories and KYAN Technologies announced a collaboration to validate and provide the KYAN test, Optim.AI™, across the United States.
Developed through evidence-driven clinical innovation and designed to deliver clarity on drug and alcohol use, our testing delivers results that advance understanding and improve outcomes.